%20-%201%20mL?unique=356783c)
Influenza B Virus (Strain: Brisbane/33/08) - 1 mL
This kit is an essential tool for professionals seeking to conduct detailed analyses of neurotransmitter levels in urine, aiding in the understanding and management of various neurological and psychiatric conditions.
Internal Reference:
BiCZ-0806
Website URL:
/shop/bicz-0806-influenza-b-virus-strain-brisbane-33-08-1-ml-431753
Influenza B Virus (Strain: Brisbane/33/08)
The Influenza B Virus (Strain: Brisbane/33/08) is a laboratory-adapted virus strain from the B/Victoria lineage, isolated in Brisbane, Australia, in 2008. It is widely used as a reference material in influenza research, diagnostic assay validation, vaccine quality control, and virus neutralization studies.
This product is supplied in a 1 mL volume, typically at a defined infectious titer (e.g., ≥10⁶ TCID₅₀/mL), suspended in a suitable viral transport medium or phosphate-buffered saline. The virus is propagated in MDCK (Madin-Darby Canine Kidney) cells, a standard host line for influenza virus amplification.
Technical Characteristics
| Feature | Description |
|---|---|
| Virus Family | Orthomyxoviridae |
| Genome | Segmented, negative-sense, single-stranded RNA |
| Strain Name | B/Brisbane/33/2008 |
| Lineage | B/Victoria |
| Passage History | Typically low-passage, MDCK-amplified |
| Formulation | Liquid suspension |
| Volume | 1 mL |
| Titer (approx.) | ≥10⁶ TCID₅₀/mL (batch-specific) |
| Biosafety Level | BSL-2 |
| Storage | -80°C; avoid freeze-thaw cycles |
Genome Structure
The Influenza B virus contains 8 RNA segments coding for:
- Hemagglutinin (HA) – major surface glycoprotein, binds to sialic acid on host cells.
- Neuraminidase (NA) – releases progeny virions.
- Polymerase complex (PB1, PB2, PA) – RNA-dependent RNA polymerase components.
- Nucleoprotein (NP) – encapsidates the RNA segments.
- Matrix (M1, M2) – viral structure and ion channel activity.
- Non-structural proteins (NS1, NS2) – host immune modulation and nuclear export.
The HA gene of Brisbane/33/08 shows amino acid changes from previous B/Victoria strains, making it important for evaluating immune escape and antigenic drift.
Applications
- Reference Strain for Vaccine Studies: Used in hemagglutination inhibition (HI) and microneutralization assays to test vaccine-induced antibodies.
- Molecular Assay Development: Calibration of qRT-PCR primers and probes for Influenza B lineage discrimination.
- Antiviral Screening: In vitro models for assessing candidate compounds against Influenza B replication.
- Serological Assays: Used in ELISA and lateral flow formats for B/Victoria antigen detection.
- Infectivity Testing: Standard for quantifying TCID₅₀ or PFU in controlled infection models.
Handling Guidelines
- Thaw on ice immediately before use.
- Gently mix without vortexing to maintain viral particle integrity.
- Use biosafety cabinet and BSL-2 practices.
- Aliquot post-thaw if repeat use is expected to avoid freeze-thaw damage.
- Dispose using validated viral inactivation protocols.
Storage and Stability
- Long-term storage at -80°C.
- Stable for up to 12 months if unopened and correctly frozen.
- Avoid >2 freeze-thaw cycles to maintain infectivity.
- If diluted, store working solution at 4°C and use within 24 hours.
Documentation and Testing
- Sterility-tested (mycoplasma, bacterial/fungal contamination)
- Titer determined via TCID₅₀, plaque assay, or qPCR.
- Genetic identity confirmed via segmental RT-PCR and Sanger or NGS sequencing.
- Certificate of Analysis (CoA) provided with each batch.
Use Restrictions
- For research use only (RUO).
- Not for diagnostic or therapeutic purposes.
- Not for use in human or animal subjects.
